ELAC2 helps your cells trim small RNA pieces that are needed to make proteins, especially inside mitochondria, the parts of cells that produce energy. When the ELAC2 gene does not work properly, cells may struggle to make energy, and organs with high energy needs, such as the heart, brain, and muscles, can be affected. Some people with harmful ELAC2 variants develop heart muscle disease, growth or feeding problems, developmental delay, or hearing changes. Many variants are harmless, while a few may change how the gene works.
What is a gene?
Genes are stretches of DNA that give cells instructions for making molecules or directing activities in the body. Some genes provide the code for proteins, which do the work inside cells. Others mainly regulate when certain processes happen, where they take place, and how active they are. Together, genes affect how the body grows and functions, and they can influence how you respond to food, stress, and medications. For a more detailed look at this subject, you can find more information in the LearnHub.
Overview
ELAC2Gene function
What if the gene works
The ELAC2 gene helps cells process transfer RNA, a helper molecule used to build proteins. This supports mitochondria, the parts of cells that produce energy, and helps high energy tissues work normally.
Risk
What if the gene does not work
Biallelic severe variants in the ELAC2 gene can cause a mitochondrial condition, often with infant-onset heart muscle disease and developmental delay; milder variants may lead to later or less severe features.
Treatment
What does that mean for your treatment
No treatment approach or drug choice is currently guided by pathogenic variants in the ELAC2 gene in clinical guidelines. The ELAC2 gene is being studied in mitochondrial disease and prostate cancer research, including as a possible biomarker, but this does not currently guide routine therapy.
Conditions associated with ELAC2
Gene function
What if the gene works
Your cells need ELAC2 to finish small RNA tools called transfer RNAs, which help assemble proteins. Much of this work is especially important in mitochondria, the parts of cells that make energy. When ELAC2 works properly, these RNA molecules are cut to the right length so protein production and energy making can stay on track.
ELAC2 trims extra material from the tail end of immature transfer RNAs. This helps turn them into mature molecules that can take part in normal protein building.
In mitochondria, ELAC2 helps cut long starter RNA strands into usable pieces by finishing the transfer RNA sections. This is a key part of what the ELAC2 gene does in mitochondria to keep RNA handling organized.
Mature transfer RNAs carry amino acids, the building blocks of proteins, to the cell's protein-making machinery. By preparing these RNAs, ELAC2 supports steady protein production, especially inside mitochondria.
Because mitochondria need their own proteins to release energy from food, ELAC2 indirectly supports normal energy production. When this RNA processing runs smoothly, cells can better meet everyday energy demands.
What is a variant?
A genetic variant is a minor change in a gene’s DNA sequence. These changes are common and help shape normal human diversity, including differences in appearance, metabolism, and the way the body responds to environmental influences. Many variants have no noticeable effect and are simply part of natural genetic variation. Sometimes, though, a variant changes gene function more significantly and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Variants in the ELAC2 gene can change the protein's shape or stability, so mitochondria, the parts of cells that make most energy, do a poorer job of processing helper RNA needed to build proteins. This is how variants in the ELAC2 gene affect cell energy. Some changes only partly reduce activity, while more severe variants can leave little or no activity, and people with two severe variants often have earlier, more pronounced features.
How variants are linked to conditions
Pathogenic variants in both copies of the ELAC2 gene can cause a rare mitochondrial condition called combined oxidative phosphorylation deficiency 17. This ELAC2 gene condition is most often linked to heart muscle disease, feeding or growth problems, developmental delay, and high lactate levels on testing. Some studies have also looked at the ELAC2 gene and prostate cancer risk, but that association is less firmly established than the rare inherited childhood condition.
A variant is not necessarily a diagnosis
Genetic variants are a routine part of human biology and are common across the general population. Most do not have a direct impact on health and instead reflect normal human variation. For many genes, carrying a variant associated with a condition indicates a possible link rather than a definite diagnosis, especially when several genes and environmental factors also contribute. In some situations, however, a single well-characterized variant in a specific gene is enough to confirm a diagnosis.
Are there things that can increase or change my risk?
For people with an ELAC2 variant linked to prostate cancer risk, age, family history, and African ancestry can further raise overall risk. There is not enough evidence to say that any specific lifestyle change lowers ELAC2-related genetic risk, though general prostate health habits still matter for overall well-being.
Inheritance of ELAC2 variants
For families asking how ELAC2 gene variants are inherited, the well-established ELAC2-related condition follows an autosomal recessive pattern. This means a child usually inherits one nonworking copy of the ELAC2 gene from each parent. When both parents carry one variant, each pregnancy has a 25% chance of the child having the condition, a 50% chance of being a carrier, and a 25% chance of inheriting neither variant. Because ELAC2 is on chromosome 17, this pattern is the same for boys and girls.
What does my ELAC2 result mean for my family?
For families of someone with an ELAC2-related condition, the pattern is usually recessive, so parents are often healthy carriers and brothers or sisters may also be carriers or, less often, have the condition. Other close relatives on both sides of the family may also carry the same gene change. The meaning for relatives can differ from the older, less certain reports linking ELAC2 to prostate cancer risk.
Genetic information
Genetic testing
How you find out about variants
To find out whether you carry a variant in the ELAC2 gene, ELAC2 genetic testing uses blood, saliva, or a cheek swab to read your DNA. Labs may look only at the ELAC2 gene or include it in a larger inherited condition panel. Results can show a benign variant, a pathogenic variant, or an uncertain finding.
When should I consider getting a genetic test?
Genetic testing for the ELAC2 gene may be considered when a baby or child has a serious heart muscle condition, especially along with low muscle tone, feeding problems, slow development, or a family history of a similar illness. It can also help clarify the cause when close relatives are known to carry an ELAC2 change.
A genetic result is only one part of your health story
A genetic finding can provide useful insight, but how much it explains depends on the condition and on the kind of variant involved. Many factors also shape how the body works over time, including lifestyle, environment, age, and medical history. For some conditions, especially those influenced by many genes, genetic information offers context rather than certainty and is best understood together with other parts of care. In other situations, a genetic result may give a clear answer. In areas like medication response, these results can help make sense of individual experiences.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how people respond to medicines. Small differences in a person’s DNA can change how the body breaks down a drug, moves it through the body, or responds at the target the medicine is meant to act on. This helps explain why the same treatment may work well for one person, have little effect in another, or cause more side effects in someone who is more sensitive to it.
What is Pharmacogenetics?
Pharmacogenetics looks at how genetic differences shape a person’s response to medications. It examines links between genes and drugs to help explain why the same treatment may work differently from one person to the next. With many medicines, genes can affect both how strongly a drug works and how the body handles it. This understanding can support more informed and individualized treatment decisions. You can learn more about this topic in the LearnHub.
Drugs influenced by the ELAC2 gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in predicting how medicines will work or which side effects may happen. Questions about medications, side effects, or new health concerns are best discussed with your doctor.
History
ELAC2 entered medical genetics through research on inherited prostate cancer in the late 1990s and early 2000s. Initially understood only through family patterns, later recognized as tied to a specific gene, it was first reported as a prostate cancer susceptibility gene and was also called HPC2 in early studies. This drew attention because researchers were trying to explain why prostate cancer seemed to cluster in some families. Over time, larger studies gave a more mixed picture, showing that some ELAC2 variants may play a smaller role in risk than first thought. The way this gene was viewed has shifted over time. Today, ELAC2 remains part of the history of early efforts to map inherited cancer risk, especially in prostate cancer research.